Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Guillaume Bonnefois"'
Autor:
Nassim Djebli, Pierre-Olivier Tremblay, Vincent Buchheit, Mario González-Sales, Guillaume Bonnefois, Georgina Meneses-Lorente, Francois Mercier, Nicolas Frey
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:997-1007
Entrectinib (ROZLYTREK®) is a CNS-active, potent, and selective inhibitor of ROS1, TRK A/B/C, and ALK kinase activity. It was recently approved for the treatment of ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.
Autor:
Marie-Pierre Dubé, Jean-Claude Tardif, Jun Li, Jean-Lucien Rouleau, Fahima Nekka, Steven Sanche, Guillaume Bonnefois, Michel White, Imad Kassem, Simon de Denus, Jacques Turgeon
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 1, Pp 194-203 (2021)
Clinical and Translational Science, Vol 14, Iss 1, Pp 194-203 (2021)
Heart failure (HF) causes pathological changes in multiple organs, thus affecting the pharmacokinetics (PK) of drugs. The aim of this study was to investigate the PK of candesartan in patients with HF while examining significant covariates and their
Publikováno v:
Clinical and translational science. 15(4)
The recently released revised vancomycin consensus guideline endorsed area under the concentration-time curve (AUC) guided monitoring. Means to AUC-guided monitoring include pharmacokinetic (PK) equations and Bayesian software programs, with the latt
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 49(2)
To evaluate study designs and the influence of dispersion of body size, body composition and maturation of clearance or reliable estimation of allometric exponents. Non-linear mixed effects modeling and parametric bootstrap were employed to assess ho